Corvus Pharmaceuticals, Inc. (CRVS)
10.90
-0.03
(-0.27%)
USD |
NASDAQ |
Oct 02, 16:00
10.91
+0.01
(+0.09%)
After-Hours: 20:00
Corvus Pharmaceuticals Enterprise Value : 702.42M for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 702.42M |
| October 01, 2026 | 704.94M |
| September 30, 2026 | 754.57M |
| September 29, 2026 | 774.76M |
| September 28, 2026 | 784.02M |
| September 25, 2026 | 762.98M |
| September 24, 2026 | 778.13M |
| September 23, 2026 | 840.38M |
| September 22, 2026 | 916.08M |
| September 21, 2026 | 830.28M |
| September 18, 2026 | 842.06M |
| September 17, 2026 | 841.22M |
| September 16, 2026 | 814.30M |
| September 15, 2026 | 874.87M |
| September 14, 2026 | 888.32M |
| September 11, 2026 | 871.50M |
| September 10, 2026 | 874.02M |
| September 09, 2026 | 906.83M |
| September 08, 2026 | 957.30M |
| September 04, 2026 | 996.00M |
| September 03, 2026 | 1.018B |
| September 02, 2026 | 980.02M |
| September 01, 2026 | 985.91M |
| August 31, 2026 | 966.56M |
| August 28, 2026 | 976.65M |
| Date | Value |
|---|---|
| August 27, 2026 | 1.024B |
| August 26, 2026 | 1.025B |
| August 25, 2026 | 1.010B |
| August 24, 2026 | 970.76M |
| August 21, 2026 | 1.002B |
| August 20, 2026 | 990.95M |
| August 19, 2026 | 1.081B |
| August 18, 2026 | 1.033B |
| August 17, 2026 | 1.040B |
| August 14, 2026 | 1.038B |
| August 13, 2026 | 1.059B |
| August 12, 2026 | 1.052B |
| August 11, 2026 | 1.025B |
| August 10, 2026 | 941.32M |
| August 07, 2026 | 956.46M |
| August 06, 2026 | 951.42M |
| August 05, 2026 | 957.30M |
| August 04, 2026 | 956.46M |
| August 03, 2026 | 910.20M |
| July 31, 2026 | 900.94M |
| July 30, 2026 | 895.05M |
| July 29, 2026 | 882.44M |
| July 28, 2026 | 905.15M |
| July 27, 2026 | 872.34M |
| July 24, 2026 | 884.96M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.551B |
| Alnylam Pharmaceuticals, Inc. | 29.06B |
| Savara, Inc. | 845.34M |
| Vericel Corp. | 1.987B |
| Biogen, Inc. | 39.55B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -17.96M |
| Total Expenses (Quarterly) | 17.96M |
| EPS Diluted (Quarterly) | -0.1944 |
| Earnings Yield | -5.67% |
| Normalized Earnings Yield | -5.667 |